Isopeptidases in anticancer therapy: Looking for inhibitors

American Journal of Translational Research

Volumn 2, Issue 3, 2010, Pages 235-247

  Sgorbissa, Andrea ^a   Potu, Harish ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Apoptosis; Cancer; Caspase; DUBs; Isopeptidase; Necrosis; Proteasome; USP

Indexed keywords

2 METHYL N [1 (2 NAPHTHYL) ETHYL] BENZAMIDE DERIVATIVE; 33 AMINO 2 KETO 7H THIENO[2,3 B]PYRIDIN 6 ONE; 9 OXO 9H INDENO[1,2 B]PYRAZINE 2,3 DICARBONITRILE DERIVATIVE; BORTEZOMIB; CYANOIDENOPYRAZINE DERIVATIVE; ENZYME INHIBITOR; GRL 0617; HBX 28 218; HBX 28 231; HBX 41108; ISATIN DERIVATIVE; MERCAPTOPURINE; N,N0 4,40 BI PHENYLDIYLBIS (4 ETHYLBENZENESULFONAMIDE); NSC 638646; NSC 687852; PEPTIDASE; PROTEASOME INHIBITOR; TIOGUANINE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER THERAPY; CELL PROLIFERATION; DRUG CONJUGATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

EID: 77954684343     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Hershko A, Ciechanover A. The Ubiquitin System. Annu Rev Biochem 1998; 67: 425-479.
2. Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochem Biophys Acta 2004; 1695: 55-72.
3. Kerscher O, Felberbaum R, Hochstrasser M. Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins. Annu Rev Cell Dev Biol 2006; 22: 159-180.
4. Hochstrasser M. Origin and function of ubiquitinlike proteins. Nature 2009; 458: 422-429.
5. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. "Protein Modifications: Beyond the Usual Suspects." EMBO Rep 2008; 9: 536-542.
6. Finley D. Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome. Annu Rev Biochem 2009; 78: 477-513.
7. Chen ZJ, Sun LJ. Nonproteolytic Functions of Ubiquitin in Cell Signaling. Mol Cell 2009; 33: 275-286.
8. Kodadek T. No Splicing, No Dicing: Non Proteolytic Roles of the Ubiquitin Proteasome System In Transcription. J Biol Cell 2010; 285: 2221-2226
9. Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem 2008; 9 Suppl 1:S1.
10. Brancolini C. Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated? Curr Mol Pharmacol 2008; 1: 24-37.
11. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochem Biophys Acta 2004; 1695: 189-207.
12. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A Genomic and Functional Inventory of Deubiquitinating Enzymes. Cell 2005; 123: 773-786.
13. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and Cellular Roles of Ubiquitin-Specific Deubiquitinating Enzymes. Annu Rev Biochem 2009; 78: 363-397.
14. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA, Mullally JE, Moos PJ, Edes K, Fitzpatrick FA. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 2001; 276: 30366-30373.
15. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of New Compounds That Trigger Apoptosome-Independent Caspase Activation and Apoptosis. Cancer Res 2006; 66: 9235-9244.
16. Berndtsson M, Beaujouin M, Rickardson L, Havelka AM, Larsson R, Westman J, Liaudet-Coopman E, Linder S. Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitinproteasome system. Int J Cancer 2009; 124: 1463-1469.
17. Komander D, Clague MJ, Urbé S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
18. Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J 2008; 414: 161-175.
19. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009; 8: 1688-1697.
20. Watson IR, Irwin MS. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 2006; 8: 655-666.
21. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Diff 2010; 17: 86-92.
22. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805.
23. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NFkappaB. Nature 2003; 424: 797-801.
24. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-796.
25. Oliveira AM, Hsi BL, Weremowicz S, Rosenberg AE, Dal Cin P, Joseph N, Bridge JA, Perez-Atayde AR, Fletcher JA. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004; 64: 1920-1923.
26. Shembade N, Ma A, Harhaj EW. Inhibition of NFkappa-B Signaling by A20 Through Disruption of Ubiquitin Enzyme Complexes. Science 2010; 327: 1135-1139.
27. Sacco JJ, Coulson JM, Clague MJ, Urbé S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB 2010; 62: 140-157.
28. Chabner BA, Roberts TG Jr. Chemotherapy and the war on cancer. Nature Rev Cancer 2005; 5: 65-72.
29. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885.
30. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010; 38: 137-143.
31. Mullally JE, Fitzpatrick FA. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 2002; 62: 351-358.
32. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21: 185-210.
33. Nicholson B, Leach CA, Goldenberg SJ, Francis DM, Kodrasov MP, Tian X, Shanks J, Sterner DE, Bernal A, Mattern MR, Wilkinson KD, Butt TR. Characterization of ubiquitin and ubiquitin-likeprotein isopeptidase activities. Protein Sci 2008; 17: 1035-1043.
34. Fontanini A, Foti C, Potu H, Crivellato E, Maestro R, Bernardi P, Demarchi F, Brancolini C. The Isopeptidase Inhibitor G5 Triggers a Caspaseindependent Necrotic Death in Cells Resistant to Apoptosis: a comparative study with the proteosome inhibitor bortezomib. J Biol Chem 2009; 284: 8369-8381.
35. Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, Brancolini C. Characterization of caspase-dependent and caspaseindependent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Mol Cancer Ther 2009; 8: 3140-3150.
36. Chen X, Chou CY, Chang GG. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir Chem Chemother 2009; 19: 151-156.
37. Chen Z, Wang Y, Ratia K, Mesecar AD, Wilkinson KD, Baker SC. Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol 2007; 81: 6007-6018.
38. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568.
39. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009; 138: 838-854.
40. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007; 32: 37-43.
41. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 Family Reunion. Mol Cell 2010; 37: 299-310.
42. Demarchi F, Brancolini C. Altering protein turnover in tumor cells: new opportunities for anticancer therapies. Drug Resist Updat 2005; 8: 359-368.
43. Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 2005; 12: 1240-1254.
44. Chauhan, D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui, H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino, MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 5: 407-419.
45. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitinmediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000; 275: 21648-21652.
46. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAILinduced apoptosis. J Biol Chem 2002; 277: 22320-22329.
47. Peter ME. The flip side of FLIP. Biochem J 2004; 3822 e1-e3.
48. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS, Sistonen L, Eriksson JE. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005; 280: 27345-27355.
49. Sayers TJ, Brooks AD, Koh CY, Ma W, Sek N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303-310.
50. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling. Cell 2009; 137: 604-606.
51. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, Kneteman NM Hao C. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955.
52. Wang Z, Aris VM, Ogburn KD, Soteropoulos P, Figueiredo-Pereira ME. Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells. J Biol Chem 2006; 281: 21377-21386.
53. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008; 90: 270-283.
54. Storer AC, Menard R. Catalytic mechanism in papain family of cysteine peptidases. Methods Enzymol 1994; 244: 486-500.
55. Hu M, Li P, Li M, Li W, Yao T, Wu J W, Gu W, Cohen R E, Shi Y. Crystal structure of a UBPfamily deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 2002; 111: 1041-1054.
56. Reyes Turcu FE, Shanks JR, Komander D, WilkinsonKD. Recognition of polyubiquitin isoforms by the multiple ubiquitin binding modules of isopeptidase. J Biol Chem 2008; 283: 19581-19592.
57. Avvakumov GV, Walker JR, Xue S, Finerty Jr PJ, Mackenzie F, Newman EM, Dhe-Paganon S. Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem 2006; 281: 38061-38070.
58. Renatus M, Parrado SG, D'Arcy A, Eidhoff U, Gerhartz B, Hassiepen U, Pierrat B, Riedl R, Vinzenz D, Worpenberg S, Kroemer M. Structural Basis of Ubiquitin Recognition by the Deubiquitinating Protease USP2. Structure 2006; 14: 1293-1302.
59. Hu M, Li P, Song L, Jeffrey PD, Chenova TA, Wilkinson KD, Cohen RE, Shi Y. Structure and mechanisms of the proteasome associated deubiquitinating enzyme USP14. EMBO J 2005; 21: 3747-3756.
60. Engels IH, Daguia C, Huynh T, Urbina H, Buddenkotte J, Schumacher A, Caldwell JS, Brinker A. A time-resolved fluorescence resonance energy transfer-based assay for DEN1 peptidase activity. Anal Biochem 2009; 390: 85-87.
61. Arnold JJ, Bernal A, Uche U, Sterner DE, Butt TR, Cameron CE, Mattern MR. Small ubiquitin-like modifying protein isopeptidase assay based on poliovirus RNA polymerase activity. Anal Biochem 2006; 350: 214-221.
62. Nicholson B, Leach CA, Goldenberg SJ, Francis DM, Kodrasov MP, Tian X, Shanks J, Sterner DE, Bernal A, Mattern MR, Wilkinson KD, Butt TR. Characterization of ubiquitin and ubiquitin-likeprotein isopeptidase activities. Protein Sci 2008; 17: 1035-1043.
63. Kang SH, Park JJ, Chung SS, Bang OS, Chung CH. Strategies for assaying deubiquitinating enzymes. Methods Enzymol 2005; 398: 500-508.
64. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT Jr. Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line. Chem Biol 2003; 10: 837-846.
65. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004; 279: 13256-13264.
66. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, Lee KJ. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009; 28: 117-127.
67. Rolén U, Freda E, Xie J, Pfirrmann T, Frisan T, Masucci MG. The ubiquitin C-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation. J Cell Mol Med 2008; 13: 1666-1678.
68. Mermerian AH, Case A, Stein RL, Cuny GD. Structure- activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin Cterminal hydrolase-L1 (UCH-L1) inhibitors. Bioorganic & Medicinal Chemistry Letters 2007; 17: 3729-3732.
69. Mitsui T, Hirayama K, Aoki S, Nishikawa K, Uchida K, Matsumoto T, Kabuta T, Wada K. Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening. Neurochemistry International 2010; 56: 679-686.
70. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004; 428:1 p following 486
71. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886.
72. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, Pandolfi PP. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-817.
73. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F, Maurice MM, Burgering BM. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature Cell Biol 2006; 8: 1064-1073.
74. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J, Calabrese A, Borg-Capra C, Sippl W, Collura V, Boissy G, Rain JC, Guedat P, Delansorne R, Daviet L. Small-molecule inhibit tor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-2295.
75. Lopez R, Collura V, Sippl W, Colland F. Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications. Eur Pat 2009 Application 09305030.0.
76. Wiliams RL, Urbé S. The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 2007; 8: 355-368.
77. Colombo M, Vallese S, Peretto I, Jacq X, Rain JC, Colland F, Guedat P. Synthesis and Biological Evaluation of 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes. ChemMed-Chem 2010; 5: 552-558.
78. Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, Chaudhuri R, Fu W, Prabhakar BS, Johnson ME, Baker SC, Ghosh AK, Mesecar AD. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008; 105: 16119-24.
79. Novartis AG. WO2007009715; 2007
80. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107.
81. Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an Important Regulator of the Susceptibility to IFN-α and Drug-Induced Apoptosis. Cancer Res 2010; 70: 1-11.
82. Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh, HL, Bernards R, D'Andrea AD. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006; 8: 339-347.
83. Graner, E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken, D, Zimmermann J, Signoretti S, Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253-261.
84. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas, DP, Lane DP, Saville M K. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26: 976-986.
85. Nicassio F, Corrado N, Vissers JH, Areces LB, Bergink S, Marteijn JA, Geverts B, Houtsmuller AB, Vermeulen W, Di Fiore PP, Citterio E. Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr Biol 2007; 17: 1972-1977.
86. Zhao B, Schlesiger C, Masucci MG, Lindsten K. The ubiquitin specific protease 4 (Usp4) is a new player in the Wnt signalling pathway. J Cell Mol Med 2009; 13: 1886-1895.
87. Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 2009; 284: 5030-5041.
88. Mizuno E, Iura T, Mukai A, Yoshimori T, Kitamura N, Komada M. Regulation of epidermal growth factor receptor down-regulation by UBPY -mediated deubiquitination at endosomes. Mol Biol Cell 2005; 16: 5163-5174.
89. Niendorf S, Oksche A, Kisser A, Löhler J, Prinz M, Schorle H, Feller S, Lewitzky M, Horak I, Knobeloch KP. Essential role of ubiquitinspecific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol. 2007; 27: 5029-39.
90. Ma YM, Boucrot E, Villén J, Affarel B, Gygi SP, Göttlinger HG, Kirchhausen T. Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation. J Biol Chem. 2007; 282: 9805-12
91. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005; 310: 1499-504.
92. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 2009; 136: 123-35.
93. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells. 1999;4: 757-67.
94. Nagai H, Noguchi T, Homma K, Katagiri K, Takeda K, Matsuzawa A, Ichijo H. Ubiquitin-like sequence in ASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell. 2009; 36: 805-18.
95. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 Regulates p53 Localization and Stability by Deubiquitinating p53. Cell 2010; 140: 1-13.
96. Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ, Cortez D. Sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem. 2010.[Epub ahead of print]
97. Yamaguchi T, Kimura J, Miki Y, Yoshida K. The deubiquitinating enzyme USP11 controls an IkB kinase α (IKKα)-p53 signaling pathway in response to tumor necrosis factor α (TNFα). J Biol Chem 2007; 282: 33943-33948.
98. Shinji S, Naito Z, Ishiwata S, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, Seya T, Matsuda A, Katsuta M and Tajiri T. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncology Rep 2006; 15: 539-543.
99. Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P, Chang C, Wang H. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 2007; 449: 1068-1072.
100. Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender, U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA. USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem 2009; 284: 9587-9595.
101. Duex JE, Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Mol Biol Cell 2009; 20: 1833-1844.
102. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun. 2002; 294: 700-9.
103. Berthouze M, Venkataramanan V, Li Y, Shenoy SK. The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor recycling and resensitization. EMBO J. 2009; 28: 1684-96.
104. Li Z, Wang D, Messing EM, Wu G. VHL proteininteracting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 2005; 6: 373-8.
105. Nakagawa T, Kajitani T, Togo S, Masuko N, Ohdan H, Hishikawa Y, Koji T, Matsuyama T, Ikura T, Muramatsu M, Ito T. Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di-and trimethylation. Genes Dev 2008; 22: 37-49.
106. Xu G, Tan X, Wang H, Sun W, Shi Y, Burlingame S, Gu X, Cao G, Zhang T, Qin J, Yang J. Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor alpha-induced nuclear factor kappaB activation via binding to and deubiquitinating receptor-interacting protein 1. J Biol Chem. 2010; 285:969-78.
107. Zhang XY, Pfeiffer HK, Thorne AW, McMahon SB. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008; 7: 1522-4.
108. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774.
109. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529-542.
110. Van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH. Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle. 2008; 7: 2710-9.
111. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, McDonald ER 3rd, Li MZ, Hannon GJ, Sorger PK, Kirschner MW, Harper JW, Elledge SJ. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature. 2007; 446: 8 76-81.
112. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. Identification of the familial cylindromatosis tumoursuppressor gene. Nat Genet. 2000; 25: 160-5.
113. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004; 430: 694-9.